The move to sell blockbuster obesity drugs like Wegovy through discounted telehealth subscriptions is reshaping the entire pharmaceutical distribution model. The platforms at the centre of this shift could be among the biggest beneficiaries of one of healthcare's fastest-growing markets.
Telehealth platforms combining pharmaceutical access with ongoing care are building sticky, subscription-based revenue streams — the kind investors love. As more patients lock in to long-term treatment plans, these companies stand to grow steadily alongside them.
Professional analysts have been closely watching this space since Novo Nordisk's strategic pivot, with several companies in this group attracting increased institutional interest. Being early to a theme like this — before it becomes mainstream news — is exactly the kind of opportunity Nemo was built for.
This basket's total market capitalisation is approximately 34,333.28 and is heavily anchored by a few very large-cap stocks. That concentration means the basket's behaviour is generally driven by its largest constituents.
DXCM: $24.17B
MED: $112.00M
GPCR: $3.41B
Novo Nordisk's move to offer discounted multi-month telehealth subscriptions for Wegovy signals a major shift in how obesity drugs reach patients. Telehealth platforms are evolving from simple video call services into full distribution networks that blend pharmaceutical access with ongoing clinical care. This creates a powerful, recurring revenue opportunity for the digital health companies sitting at the centre of this transformation.
This group spans a range of companies — from telehealth infrastructure providers and virtual coaching platforms to drug developers working on next-generation obesity treatments. Some are established businesses with existing patient bases, while others are earlier-stage companies with higher growth potential and higher risk. Together, they offer broad exposure to a rapidly evolving corner of the healthcare market.
These stocks were handpicked by professional analysts to capture the companies most likely to benefit from the direct-to-consumer digital health shift driven by obesity drug subscriptions. Each one plays a distinct role in the ecosystem — whether delivering care, developing drugs, tracking metabolic data, or providing the technology backbone for virtual clinics. They were not chosen at random; they represent a carefully considered view of where this market is heading.
Novo Nordisk has launched a discounted telehealth subscription model for its popular Wegovy treatments to counter rising competition. This shift creates compelling investment opportunities in the digital health platforms that are becoming vital distribution channels for blockbuster obesity drugs.
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Veröffentlicht am April 1
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+3
Here are a few of the assets in this group. Create an account to unlock the full list.
DEXCOM INC
DXCM
Aktueller Kurs
$83.03
DexCom's continuous glucose monitors provide the metabolic data tracking that telehealth providers increasingly use to monitor patients on obesity dru...
DexCom's continuous glucose monitors provide the metabolic data tracking that telehealth providers increasingly use to monitor patients on obesity drugs.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+386.70%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 386.7 % zulegen.
10 von 12 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
